SEC Tracker
Get the app

BioAge Labs BIOA

BioAge announces indication expansion for oral NLRP3 inhibitor BGE-102

Form
8-K
Filed
Importance
Routine
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when BioAge Labs files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Caribou Biosciences CRBU public float $113M, Jun 30, 2025
  2. Fate Therapeutics FATE public float $113M, Jun 30, 2025
  3. Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
  4. Protara Therapeutics PRTO public float $112M, Jun 30, 2025
  5. TuHURA Biosciences HURA public float $111M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.